论文部分内容阅读
目的探讨蛋白酶体抑制剂治疗多发性骨髓瘤的临床疗效。方法选取2010年6月-2012年1月采用传统VADT方案进行治疗的15例多发性骨髓瘤患者为对照组,同期采用以蛋白酶体抑制剂为主VDT方案进行治疗的15例患者为观察组,将两组治疗总有效率、不良反应发生率及血红蛋白增高20 g/L及以上者比例、骨髓浆细胞降至5%以下者比例进行比较。结果观察组的治疗总有效率和血红蛋白增高20 g/L及以上、骨髓浆细胞降至5%以下者比例均高于对照组,不良反应发生率低于对照组,P均<0.05,差异有统计学意义。结论蛋白酶体抑制剂治疗多发性骨髓瘤的临床疗效好,安全性也较受认可,优势明显。
Objective To investigate the clinical efficacy of proteasome inhibitor in the treatment of multiple myeloma. Methods Fifteen patients with multiple myeloma who underwent traditional VADT regimen from June 2010 to January 2012 were selected as the control group. Fifteen patients treated by proteasome inhibitor-based VDT over the same period were selected as the observation group, The two groups of total effective rate, the incidence of adverse reactions and hemoglobin increased 20 g / L and above, the ratio of bone marrow cells to 5% or less were compared. Results The total effective rate of observation group and hemoglobin increased 20 g / L and above, bone marrow cells to 5% or less were higher than the control group, the incidence of adverse reactions was lower than the control group, P <0.05, the difference was Statistical significance. Conclusions The proteasome inhibitor is effective and safe in the treatment of multiple myeloma. The advantages are obvious.